S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

AMRX

Amneal Pharmaceuticals, Inc. AMRX

$17.85 -0.19 (-1.05%)

Extended · +1.85σ Grade C

+ Compare Open in Sniper

News · AMRX

Full news feed →

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

GlobeNewswire Inc. · 15h ago

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight

GlobeNewswire Inc. · 43d ago

Why Is Amneal Pharmaceuticals Stock Gaining Today?

Benzinga · 86d ago

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

GlobeNewswire Inc. · 94d ago

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

Benzinga · 154d ago

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

Benzinga · 171d ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

GlobeNewswire Inc. · 224d ago

Amneal to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. · 227d ago

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

Benzinga · 281d ago

3 Lesser-Known Healthcare Names With Major Upside in Store

Investing.com · 288d ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

GlobeNewswire Inc. · 294d ago

Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging

GlobeNewswire Inc. · 308d ago

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

GlobeNewswire Inc. · 324d ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

GlobeNewswire Inc. · 364d ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

GlobeNewswire Inc. · 387d ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

GlobeNewswire Inc. · 400d ago

Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry

GlobeNewswire Inc. · 403d ago

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Benzinga · 406d ago

Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight

GlobeNewswire Inc. · 407d ago

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight

GlobeNewswire Inc. · 451d ago

Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR

GlobeNewswire Inc. · 497d ago

Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033

GlobeNewswire Inc. · 599d ago

Opioid Overdose Treatment Market is Projected to Reach US$ 3.1 Billion by 2034 | Fact.MR Report

GlobeNewswire Inc. · 676d ago

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

Benzinga · 679d ago

Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report

GlobeNewswire Inc. · 694d ago